Browsing by Author "Capek, Jan"

Sort by: Order: Results:

  • Cysteine conjugates of acetaminophen and p-aminophenol are potent inducers of cellular impairment in human proximal tubular kidney HK-2 cells 
    Rousar, Tomas; Handl, Jiri; Capek, Jan; Nyvltova, Pavlina; Rousarova, Erika; Kubat, Miroslav; Smid, Lenka; Vanova, Jana; Maliňák, Dávid; Musílek, Kamil; Cesla, Petr (Springer, 2023)
    Acetaminophen (APAP) belong among the most used analgesics and antipyretics. It is structurally derived from p-aminophenol (PAP), a potent inducer of kidney toxicity. Both compounds can be metabolized to oxidation products ...
  • Development of submicromolar 17 beta-HSD10 inhibitors and their in vitro and in vivo evaluation 
    Benek, Ondřej; Vašková, Michaela; Sedláček Miškeříková, Markéta; Schmidt, Monika; Andrýs, Rudolf; Rotterová, Aneta; Skarka, Adam; Hatlapatkova, Jana; Karasova, Jana Zdarova; Medvecký, Matej; Hroch, Lukas; Vinklářová, Lucie; Fisar, Zdenek; Hroudova, Jana; Handl, Jiri; Capek, Jan; Rousar, Tomas; Kobrlova, Tereza; Dolezal, Rafael; Soukup, Ondrej; Aitken, Laura; Gunn-Moore, Frank; Musílek, Kamil (ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2023)
    17 beta-hydroxysteroid dehydrogenase type 10 (17 beta-HSD10) is a multifunctional mitochondrial enzyme and putative drug target for the treatment of various pathologies including Alzheimer's disease or some types of ...
  • Structure-Guided Design of N-Methylpropargylamino- Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer's Disease 
    Svobodova, Barbora; Pulkrabkova, Lenka; Panek, Dawid; Misiachna, Anna; Kolcheva, Marharyta; Andrýs, Rudolf; Handl, Jiri; Capek, Jan; Nyvltova, Pavlina; Rousar, Tomas; Prchal, Lukas; Hepnarova, Vendula; Hrabinova, Martina; Muckova, Lubica; Tosnerova, Daniela; Karabanovich, Galina; Finger, Vladimir; Soukup, Ondrej; Horak, Martin; Korabecny, Jan (MDPI-Molecular diversity preservation international, 2023)
    Alzheimer's disease (AD) is a complex disease with an unknown etiology. Available treatments, limited to cholinesterase inhibitors and N-methyl-d-aspartate receptor (NMDAR) antagonists, provide symptomatic relief only. As ...

Search DSpace

Browse

My Account